Kyverna Therapeutics, Inc. (KYTX) AI Stock Analysis

• Market Cap: $275.04M
• Dividend Yield: N/A
• Average Volume (3M): 705.16K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.62
• Revenue Growth: N/A
• EPS Growth: -21.22%
• Country: US
• Employees: 112
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.85
• Shares Outstanding: 43,245,667
• 10 Day Avg. Volume: 1,153,945
• 30 Day Avg. Volume: 705,161
• PEG Ratio: >-0.01
• Price to Book (P/B): 0.54
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.23
• Enterprise Value/Market Cap: -0.27
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: 36.64
• Enterprise Value/Ebitda: 0.46
• 1Y Price Target: $23.67
• Price Target Upside: 208.20% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 36 Underperform
• Price Target: ―

Kyverna Therapeutics, Inc. faces significant financial challenges, with consistent losses and zero revenue. The company's technical indicators and valuation metrics reflect ongoing operational and financial difficulties. Key risks include negative profitability and weak market momentum, which significantly impact the stock's performance.

Positive Factors

Innovative Product Pipeline

Kyverna's focus on CAR T-cell therapies for autoimmune diseases positions it at the forefront of innovative treatments, potentially transforming patient care and expanding market opportunities.

Regulatory Progress

Advancing to a Phase 2/3 trial with FDA alignment indicates regulatory confidence in Kyverna's approach, enhancing the likelihood of successful commercialization and long-term growth.

Strong Equity Position

A strong equity position with low leverage provides financial stability, enabling Kyverna to invest in R&D and withstand market fluctuations, supporting long-term strategic initiatives.

Negative Factors

Zero Revenue

The absence of revenue generation underscores operational challenges and limits financial resources, potentially hindering growth and sustainability if not addressed.

Negative Profit Margins

Sustained negative profit margins indicate operational inefficiencies and financial strain, which could impact Kyverna's ability to invest in future growth and innovation.

Cash Flow Difficulties

Negative cash flow highlights liquidity constraints, limiting Kyverna's ability to fund operations and strategic initiatives without external financing, posing a risk to long-term viability.

Kyverna Therapeutics, Inc. Business Overview & Revenue Model

Company Description

Kyverna Therapeutics, Inc. (KYTX) is a biotechnology company focused on developing innovative cell therapies for the treatment of autoimmune diseases. The company aims to harness advanced technologies in cell engineering and immunology to provide durable and transformative solutions for patients. Kyverna's core products are centered around its proprietary KYV-101 platform, which is designed to modulate the immune system and offer new treatment options for conditions such as lupus and rheumatoid arthritis.

How the Company Makes Money

Kyverna Therapeutics makes money primarily through the development and commercialization of its cell therapy products. The company may generate revenue through partnerships and collaborations with other biotech and pharmaceutical companies, which can include upfront payments, milestone payments, and royalties on sales of co-developed therapies. Additionally, Kyverna might engage in licensing agreements for its proprietary technologies, further contributing to its revenue streams. As a biotechnology firm, Kyverna may also secure funding from investors and grants to support its research and development efforts.

Kyverna Therapeutics, Inc. Financial Statement Overview

Summary

Kyverna Therapeutics, Inc. faces significant financial challenges with consistent losses and zero revenue in the most recent period. The balance sheet reflects a strong equity position, but profitability remains a concern. Cash flow analysis indicates liquidity constraints despite recent financing activities. Improvement in revenue generation and operational efficiencies is crucial for financial health.

Income Statement

Kyverna Therapeutics, Inc. shows significant challenges in generating revenue with total revenue at zero for the latest period. Net profit margins are negative, reflecting continuous losses over the years. EBIT and EBITDA margins are also negative, indicating operational inefficiencies. The revenue growth rate cannot be calculated due to zero revenue, highlighting the company's struggle in revenue generation.

Balance Sheet

The company has a strong equity base with a low debt-to-equity ratio due to significant stockholders' equity. However, the equity ratio is high, and the company is not highly leveraged, which is a positive sign. Return on equity is negative, reflecting the ongoing losses impacting shareholder returns. Overall, while the company maintains a relatively stable balance sheet, the profitability aspect is weak.

Cash Flow

Free cash flow is negative, indicating that the company is not generating enough cash to cover its capital expenditures. Operating cash flow is also negative, underscoring operational challenges. However, the company has managed significant financing cash inflows, which may provide some liquidity buffer. The ratio of operating cash flow to net income and free cash flow to net income is not favorable, showing cash flow difficulties.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	0.00	7.03M	5.66M
Gross Profit	-1.99M	-2.13M	-1.71M	7.03M	5.66M
EBITDA	-158.93M	-125.20M	-58.47M	-27.78M	-25.76M
Net Income	-160.99M	-127.48M	-60.37M	-28.89M	-26.35M
Balance Sheet
Total Assets	187.16M	304.64M	75.19M	66.92M	85.49M
Cash, Cash Equivalents and Short-Term Investments	171.14M	285.98M	57.54M	51.32M	76.07M
Total Debt	5.02M	8.24M	9.08M	10.56M	5.55M
Total Liabilities	35.21M	38.06M	26.02M	20.25M	131.74M
Stockholders Equity	151.95M	266.59M	49.18M	46.68M	-46.25M
Cash Flow
Free Cash Flow	-158.37M	-116.45M	-53.03M	-36.88M	-23.44M
Operating Cash Flow	-157.25M	-114.25M	-52.41M	-36.11M	-22.16M
Investing Cash Flow	86.52M	-160.90M	-8.79M	-14.10M	-1.29M
Financing Cash Flow	210.00K	337.11M	58.12M	11.88M	72.52M

Kyverna Therapeutics, Inc. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 7.68
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KYTX, the sentiment is Positive. The current price of 7.68 is above the 20-day moving average (MA) of 7.10, above the 50-day MA of 6.77, and above the 200-day MA of 3.89, indicating a bullish trend. The MACD of 0.26 indicates Negative momentum. The RSI at 55.76 is Neutral, neither overbought nor oversold. The STOCH value of 55.94 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for KYTX.

Kyverna Therapeutics, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SLN	54 Neutral	$307.49M	-3.89	―	―	―	―
TRDA	54 Neutral	$385.25M	―	-27.11%	―	-71.42%	-248.91%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
AVIR	47 Neutral	$238.29M	―	-37.98%	―	―	14.33%
CDXS	42 Neutral	$143.62M	―	-114.26%	―	-17.87%	14.42%
HRTX	42 Neutral	$205.37M	―	―	―	12.60%	58.23%
KYTX	36 Underperform	$275.04M	-1.73	-70.82%	―	―	-21.22%

Kyverna Therapeutics, Inc. Corporate Events

Kyverna Therapeutics Sets 2025 Strategic Priorities for Growth

Kyverna Therapeutics announces its strategic priorities for 2025, highlighting its focus on advancing the KYV-101 CD19 CAR T-cell therapy through late-stage development and commercialization for autoimmune diseases. The company aims to achieve a first-to-market position with KYV-101 for stiff person syndrome, with a BLA filing targeted for 2026, while also expanding its pipeline with KYV-102 to enhance CAR T accessibility. The company is focusing on capital-efficient growth and has a cash runway into 2027 to support its strategic goals.